ATE199716T1 - Verbindungen die sowohl starke calcium- antagonistische und antioxydatieve aktivitaet haben und deren verwendung als zellschuetzende mittel. - Google Patents

Verbindungen die sowohl starke calcium- antagonistische und antioxydatieve aktivitaet haben und deren verwendung als zellschuetzende mittel.

Info

Publication number
ATE199716T1
ATE199716T1 AT95904837T AT95904837T ATE199716T1 AT E199716 T1 ATE199716 T1 AT E199716T1 AT 95904837 T AT95904837 T AT 95904837T AT 95904837 T AT95904837 T AT 95904837T AT E199716 T1 ATE199716 T1 AT E199716T1
Authority
AT
Austria
Prior art keywords
compounds
antioxidant activity
calcium antagonist
protective agents
cell protective
Prior art date
Application number
AT95904837T
Other languages
English (en)
Inventor
Mark Hellberg
George Barnes
Robert J Collier Jr
Original Assignee
Alcon Lab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Lab Inc filed Critical Alcon Lab Inc
Application granted granted Critical
Publication of ATE199716T1 publication Critical patent/ATE199716T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/70—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with two hydrocarbon radicals attached in position 2 and elements other than carbon and hydrogen in position 6
    • C07D311/72—3,4-Dihydro derivatives having in position 2 at least one methyl radical and in position 6 one oxygen atom, e.g. tocopherols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Furan Compounds (AREA)
  • Anti-Oxidant Or Stabilizer Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compounds Of Unknown Constitution (AREA)
AT95904837T 1993-12-08 1994-12-07 Verbindungen die sowohl starke calcium- antagonistische und antioxydatieve aktivitaet haben und deren verwendung als zellschuetzende mittel. ATE199716T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16398093A 1993-12-08 1993-12-08
PCT/US1994/014069 WO1995015958A1 (en) 1993-12-08 1994-12-07 Compounds having both potent calcium antagonist and antioxidant activity and use thereof as cytoprotective agents

Publications (1)

Publication Number Publication Date
ATE199716T1 true ATE199716T1 (de) 2001-03-15

Family

ID=22592463

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95904837T ATE199716T1 (de) 1993-12-08 1994-12-07 Verbindungen die sowohl starke calcium- antagonistische und antioxydatieve aktivitaet haben und deren verwendung als zellschuetzende mittel.

Country Status (17)

Country Link
US (1) US5646149A (de)
EP (1) EP0682664B1 (de)
JP (1) JP3150155B2 (de)
KR (1) KR960701033A (de)
CN (1) CN1100774C (de)
AT (1) ATE199716T1 (de)
BR (1) BR9406080A (de)
CA (1) CA2153979C (de)
DE (1) DE69426871T2 (de)
DK (1) DK0682664T3 (de)
ES (1) ES2156934T3 (de)
FI (1) FI953748A0 (de)
GR (1) GR3035971T3 (de)
HK (1) HK1011685A1 (de)
NO (1) NO953093L (de)
PT (1) PT682664E (de)
WO (1) WO1995015958A1 (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995034299A1 (en) * 1994-06-10 1995-12-21 Telor Ophthalmic Pharmaceuticals, Inc. Inhibition of intraoperative miosis/production of mydriasis by calcium channel blockers
US5719167A (en) * 1995-08-07 1998-02-17 Alcon Laboratories, Inc. Angiostatic compounds
US5798356A (en) * 1995-08-07 1998-08-25 Alcon Laboratories, Inc. Angiostatic compounds
JP3719609B2 (ja) 1995-12-21 2005-11-24 アルコン ラボラトリーズ，インコーポレイテッド 緑内障および眼虚血の治療のための特定のイソキノリンスルホニル化合物の使用
WO1997035852A1 (en) * 1996-03-25 1997-10-02 Alcon Laboratories, Inc. Thiazolidine-4-carboxylic acid derivatives as cytoprotective agents
JP3562903B2 (ja) * 1996-05-31 2004-09-08 セイコープレシジョン株式会社 フォーカルプレーンシャッタ
DE19718826A1 (de) * 1997-05-05 1998-11-12 Marion S Dr Eckmiller Verwendung biologisch aktiver Wirkstoffe zum Beeinflussen des Extrazellulär-Raumes von Sinneszellen und Verfahren zur Wirkstoff-Administrationssteuerung
US6951862B2 (en) * 1998-06-30 2005-10-04 Neuromed Technologies, Inc. Calcium channel blockers comprising two benzhydril moieties
US6310059B1 (en) * 1998-06-30 2001-10-30 Neuromed Technologies, Inc. Fused ring calcium channel blockers
US6492375B2 (en) 1998-06-30 2002-12-10 Neuromed Technologies, Inc. Partially saturated calcium channel blockers
US20060084660A1 (en) * 1998-06-30 2006-04-20 Neuromed Technologies Inc. Calcium channel blockers comprising two benzhydril moieties
US20040266784A1 (en) * 1998-06-30 2004-12-30 Snutch Terrance P. Calcium channel inhibitors comprising benzhydril spaced from piperazine
WO2004089922A2 (en) * 1998-06-30 2004-10-21 Neuromed Technologies, Inc. Calcium channel inhibitors comprising benzhydril spaced from piperazine
US6011035A (en) * 1998-06-30 2000-01-04 Neuromed Technologies Inc. Calcium channel blockers
US6943168B2 (en) * 1998-06-30 2005-09-13 Neuromed Technologies Inc. Calcium channel inhibitors comprising benzhydril spaced from piperazine
US6387897B1 (en) * 1998-06-30 2002-05-14 Neuromed Technologies, Inc. Preferentially substituted calcium channel blockers
US7186726B2 (en) * 1998-06-30 2007-03-06 Neuromed Pharmaceuticals Ltd. Preferentially substituted calcium channel blockers
US20040259866A1 (en) * 1998-06-30 2004-12-23 Snutch Terrance P. Calcium channel blockers comprising two benzhydril moieties
US6462066B2 (en) 1999-12-02 2002-10-08 University Of South Florida Method and composition for treatment of ischemic neuronal reperfusion injury
MXPA02006137A (es) 1999-12-20 2002-12-05 Neuromed Tech Inc Bloqueadores del canal de calcio parcialmente saturados.
US20030199523A1 (en) * 2002-02-28 2003-10-23 Snutch Terrance P. Heterocyclic calcium in channel blockers
BRPI0410871A (pt) * 2003-05-30 2006-07-04 Neuromed Tech Inc 3-aminometil-pirrolidinas como bloqueadores do canal de cálcio do tipo n
ITTO20030140U1 (it) * 2003-09-16 2005-03-17 Interfila Srl Matita cosmetica
WO2005033092A1 (en) 2003-09-19 2005-04-14 Galileo Pharmaceuticals, Inc. Chroman derivatives
US7507760B2 (en) * 2004-01-22 2009-03-24 Neuromed Pharmaceuticals Ltd. N-type calcium channel blockers
CA2562371A1 (en) * 2004-04-09 2005-10-20 Neuromed Pharmaceuticals Ltd. Diarylamine derivatives as calcium channel blockers
US20050227999A1 (en) * 2004-04-09 2005-10-13 Neuromed Technologies Inc. Diarylamine derivatives as calcium channel blockers
MX2007002410A (es) * 2004-08-30 2007-05-07 Neuromed Pharmaceuticals Ltd Derivados de urea como bloqueadores de canal de calcio.
US7511077B2 (en) * 2005-02-09 2009-03-31 Neuromed Pharmaceuticals Ltd. Diamine calcium channel blockers
CA2633457A1 (en) * 2005-12-19 2007-06-28 Neuromed Pharmaceuticals Ltd. Heterocyclic amide derivatives as calcium channel blockers
EP2007759A4 (de) * 2006-04-17 2010-12-22 Neuromed Pharmaceuticals Ltd Isoxazolderivate als calciumkanalblocker
WO2007133481A2 (en) * 2006-05-11 2007-11-22 Neuromed Pharmaceuticals Ltd. Method for increasing the bioavailability of benzhydryl piperazine containing compounds
US20100029681A1 (en) * 2006-05-26 2010-02-04 Hassan Pajouhesh Heterocyclic compounds as calcium channel blockers
CA2663280A1 (en) * 2006-09-14 2008-03-20 Neuromed Pharmaceuticals Ltd. Diaryl piperidine compounds as calcium channel blockers
EP2074105A4 (de) * 2006-10-13 2010-10-06 Neuromed Pharmaceuticals Ltd Cyclopropylpiperazinverbindungen als calciumkanalblocker
US8409560B2 (en) 2011-03-08 2013-04-02 Zalicus Pharmaceuticals Ltd. Solid dispersion formulations and methods of use thereof
WO2012122279A1 (en) 2011-03-08 2012-09-13 Zalicus Pharmaceuticals Ltd. Solid dispersion formulations and methods of use thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB705979A (en) * 1951-03-22 1954-03-24 Henri Morren 1.4-aralkyl piperazines and process for the preparation thereof
BE790971A (fr) * 1971-11-09 1973-05-07 Janssen Pharmaceutica Nv Metode ter voorkoming van patologische reakties die de funktie van het komplement vereisen
NL7306771A (de) * 1972-06-02 1973-12-04
DE2900810A1 (de) * 1979-01-11 1980-07-24 Cassella Ag Substituierte n-benzhydryl-n'-p- hydroxybenzyl-piperazine und verfahren zu ihrer herstellung
US4550022A (en) * 1981-10-05 1985-10-29 Alcon Laboratories, Inc. Tissue irrigating solution
IT1213131B (it) * 1984-02-02 1989-12-14 Yason Srl Composto ad attivita' calcio antagonista periferica, anticonvulsivante ed eumetabolica cerebrale,metodo per la sua preparazione e composizioni farmaceutiche.
JPS60222472A (ja) * 1984-03-30 1985-11-07 Kanebo Ltd 新規なピペラジン誘導体および該化合物を有効成分とする医薬組成物
WO1987005020A1 (fr) * 1986-02-21 1987-08-27 Kuraray Co., Ltd. Derives de 3,4-dihydro-2h-benzopyranne et leur usage medicinal
GB8626344D0 (en) * 1986-11-04 1986-12-03 Zyma Sa Bicyclic compounds
US5120843A (en) * 1987-04-27 1992-06-09 Upjohn Pharmaceutically active amines
EP0487510A1 (de) * 1987-04-27 1992-05-27 The Upjohn Company Pharmazeutisch wirksame Aminen
CA1338012C (en) * 1987-04-27 1996-01-30 John Michael Mccall Pharmaceutically active amines
WO1989005803A1 (fr) * 1987-12-24 1989-06-29 Kuraray Co., Ltd. Derives de 3,4-dihydro-2h-1,3-benzoxazine et leur utilisation en medecine
US5015661A (en) * 1988-08-09 1991-05-14 Hoffmann-La Roche Inc. Chromanes and their pharmaceutical compositions and methods
EP0369082A1 (de) * 1988-11-14 1990-05-23 Merrell Dow Pharmaceuticals Inc. Herzschutz-Tocopherolanaloge
TW199152B (de) * 1990-11-01 1993-02-01 Takeda Pharm Industry Co Ltd

Also Published As

Publication number Publication date
DK0682664T3 (da) 2001-07-16
HK1011685A1 (en) 1999-07-16
AU697050B2 (en) 1998-09-24
AU1336895A (en) 1995-06-27
NO953093L (no) 1995-10-09
GR3035971T3 (en) 2001-08-31
EP0682664A1 (de) 1995-11-22
FI953748L (fi) 1995-08-07
CA2153979A1 (en) 1995-06-15
DE69426871D1 (de) 2001-04-19
FI953748A7 (fi) 1995-08-07
DE69426871T2 (de) 2001-06-21
US5646149A (en) 1997-07-08
CA2153979C (en) 2003-10-21
WO1995015958A1 (en) 1995-06-15
ES2156934T3 (es) 2001-08-01
CN1117292A (zh) 1996-02-21
EP0682664B1 (de) 2001-03-14
PT682664E (pt) 2001-06-29
CN1100774C (zh) 2003-02-05
KR960701033A (ko) 1996-02-24
FI953748A0 (fi) 1995-08-07
JP3150155B2 (ja) 2001-03-26
BR9406080A (pt) 1996-02-06
NO953093D0 (no) 1995-08-07
JPH08507546A (ja) 1996-08-13

Similar Documents

Publication Publication Date Title
DE69426871D1 (de) Verbindungen die sowohl starke calcium-antagonistische und antioxydatieve aktivitaet haben und deren verwendung als zellschuetzende mittel.
DE69924500D1 (de) Chinazolinderivate
CA2144962A1 (en) 1-(2-oxo-acetyl)-piperidine-2-carboxylic acid derivatives as multi-drug-resistant cancer cell sensitizers
ATE403430T1 (de) Neue carbamate- und harnstoffderivate als mittel gegen multidrugresistenz
DK0839143T3 (da) Tetralinforbindelser med MDR-aktivitet
TR200200160T2 (tr) Antiinflamatuar ajanlar olarak imidazoller ve triazoller
YU6602A (sh) Pirimidin-2,4,6-trion metaloproteinazni inhibitori
ATE119520T1 (de) Derivate von hydroxaminsäure und von n- hydroxyharnstoff sowie ihre verwendung.
ATE413179T1 (de) Therapeutische verwendungen von steroiden bei blutzellmangelzustaenden
EP0939627A4 (de) Pentafluorobenzensulfonamide und analoge
CY1114133T1 (el) ΥΠΟΚΑΤΕΣΤΗΜΕΝΕΣ γ-ΦΑΙΝΥΛ-Δ-ΛΑΚΤΑΜΕΣ ΚΑΙ ΧΡΗΣΕΙΣ ΠΟΥ ΣΧΕΤΙΖΟΝΤΑΙ ΠΡΟΣ ΑΥΤΕΣ
PT902789E (pt) Derivados de androsteno
BR0015416A (pt) Composições contendo derivados do ácido hidroxieicosa tetraenóico e métodos de uso no tratamento de distúrbios de olhos secos
DE60045508D1 (de) Dalda-analoge und ihre verwendung
DE69919179D1 (de) Substituierte gamma-phenyl-delta-lactone und deren analoge, und ihre verwendungen
NO991734L (no) Pyrazolinoner for behandling av potensforstyrrelser
DE69514100D1 (de) Substituierte kondensierte und verbrückte bicyclische verbindungen als therapeutische mittel
ES2133918T3 (es) Nuevos esteroides seco-d activos en el sistema cardiovascular y composiciones farmaceuticas que los contienen.
YU46302A (sh) Supstituisani piroli
LV11593A (lv) Dimetikona pielietojums aizcietejumu arstesana
DE69230644D1 (de) Verwendung von protease nexin-i als mittel gegen entzündungen
BR0016168A (pt) Combinações terapêuticas de (s)-2-(benzilaminometil)-2,3,8,9tetrahidro-7h-1,4-dioxi no[2,3 -e]indol-8-ona e neurolépticos para o tratamento ou prevenção de distúrbios psicóticos
NO921691L (no) Farmasoeytisk preparat

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee